| Model Number |
9004 |
| Medical Device Problem Code |
Adverse Event Without Identified Device or Use Problem (2993)
|
| Health Effect - Clinical Code |
Reocclusion (1985)
|
| Date of Event |
08/09/2016
|
|
Type of Reportable Event
|
Serious Injury
|
|
Additional Manufacturer Narrative
|
|
Analysis: the sample(s) were not returned to the user facility; therefore, device evaluations are unable to be performed.A lot history review revealed this is the only complaints associated this lot.A review of the device history record (dhr) shows the lot was manufactured to specification.Conclusion: the actual samples were not received for evaluation.The dhr found nothing to indicate a manufacturing related cause for this event.The investigator assessed the event was not related to the study device or procedure.Based on the instructions for use (ifu), the occurrence of a reocclusion is an inherent risk of any pta procedure, and has been reported in clinical trials of drug coated balloons.If additional information becomes known to the manufacturer, a supplemental report will be provided will all relevant information.The information provided by bard represents all of the known information at this time.Despite good faith efforts to obtain additional information, the complainant / reporter was unable or unwilling to provide any further patient, product, or procedural details to bard.
|
| |
|
Event or Problem Description
|
|
It was reported that during the index procedure, two lutonix percutaneous transluminal drug coated balloon (dcb) dilatation catheter were used to treat the target lesion located in the left superficial femoral artery (sfa) and popliteal artery.Approximately 18 months after the index procedure, the patient's left sfa and popliteal vessels were reportedly reoccluded.A revascularization was performed involving normal percutaneous transluminal angioplasty (pta) and stent placement, which the hcp deemed successful.The investigator assessed the event was not related to the study device or procedure.The sample was discarded by the user facility and not available for further evaluation.No adverse patient effects were reported.This is one of two products involved with the reported event and the associated manufacturers report number is 3006513822-2016-00172.
|
| |
|
Additional Manufacturer Narrative
|
|
Additional information: the event description had the following phrase added "but the cec has adjudicated that the study device is possibly related to the event of reocclusion." conclusion the conclusion had the following phrase added "but the cec has adjudicated that the study device is possibly related to the event of reocclusion." corrected data: the udi no.Was changed from "(b)(4)" to "(b)(4)." the health professional choice was changed from "no" to "yes." (b)(4).Analysis: the sample(s) were not returned to the user facility; therefore, device evaluations are unable to be performed.A lot history review revealed this is the only complaints associated this lot.A review of the device history record (dhr) shows the lot was manufactured to specification.Conclusion: the actual samples were not received for evaluation.The dhr found nothing to indicate a manufacturing related cause for this event.The investigator assessed the event was not related to the study device or procedure, but the cec has adjudicated that the study device is possibly related to the event of reocclusion.Based on the instructions for use (ifu), the occurrence of a reocclusion is an inherent risk of any pta procedure, and has been reported in clinical trials of drug coated balloons.If additional information becomes known to the manufacturer, a supplemental report will be provided will all relevant information.
|
| |
|
Event or Problem Description
|
|
It was reported that during the index procedure, two lutonix percutaneous transluminal drug coated balloon (dcb) dilatation catheter were used to treat the target lesion located in the left superficial femoral artery (sfa) and popliteal artery.Approximately 18 months after the index procedure, the patient¿s left sfa and popliteal vessels were reportedly reoccluded.A revascularization was performed involving normal percutaneous transluminal angioplasty (pta) and stent placement, which the hcp deemed successful.The investigator assessed the event was not related to the study device or procedure, but the cec has adjudicated that the study device is possibly related to the event of reocclusion.The sample was discarded by the user facility and is not available for further evaluation.No adverse patient effects were reported.This is one of two products involved with the reported event and the associated manufacturers report number is 3006513822-2016-00172.
|
| |
|
Search Alerts/Recalls
|